D-1064-2016 Class II Terminated

Recalled by Allergan Sales, LLC — Waco, TX

FDA drug recall D-1064-2016 was initiated by Allergan Sales, LLC on May 10, 2016 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications. The recall status is terminated (terminated Dec 6, 2017). Affected quantity: 17802 units.

Recall details

Product Type
Drugs
Report Date
Jul 13, 2016
Initiation Date
May 10, 2016
Termination Date
Dec 6, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17802 units

Product description

Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612

Reason for recall

Failed Content Uniformity Specifications.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: a) 84172, b) 84173, Exp FEB/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1064-2016
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1064-2016. Report a data issue: hello@regdatalab.com.